A prostaglandin that is a powerful vasodilator and inhibits platelet aggregation. It is biosynthesized enzymatically from PROSTAGLANDIN ENDOPEROXIDES in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension (HYPERTENSION, PULMONARY).
Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS.
The process of keeping pharmaceutical products in an appropriate location.
An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.
The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it.
Delivery of substances through VENIPUNCTURE into the VEINS.
Pathological process resulting in the fibrous obstruction of the small- and medium-sized PULMONARY VEINS and PULMONARY HYPERTENSION. Veno-occlusion can arise from fibrous proliferation of the VASCULAR INTIMA and VASCULAR MEDIA; THROMBOSIS; or a combination of both.
The movement and the forces involved in the movement of the blood through the CARDIOVASCULAR SYSTEM.
A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn.
The exercise capacity of an individual as measured by endurance (maximal exercise duration and/or maximal attained work load) during an EXERCISE TEST.
Substances added to pharmaceutical preparations to protect them from chemical change or microbial action. They include ANTI-BACTERIAL AGENTS and antioxidants.
Sulfones are a class of organic compounds containing the functional group with a sulfur atom bonded to two oxygen atoms and another organic group, widely used in pharmaceuticals, particularly for the treatment of bacterial infections, leprosy, and certain types of cancer.
A dull red, firm, dome-shaped hemangioma, sharply demarcated from surrounding skin, usually located on the head and neck, which grows rapidly and generally undergoes regression and involution without scarring. It is caused by proliferation of immature capillary vessels in active stroma, and is usually present at birth or occurs within the first two or three months of life. (Dorland, 27th ed)
Drugs used to cause dilation of the blood vessels.
The simultaneous, or near simultaneous, transference of heart and lungs from one human or animal to another.
A series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases. They include ADENINE and GUANINE, constituents of nucleic acids, as well as many alkaloids such as CAFFEINE and THEOPHYLLINE. Uric acid is the metabolic end product of purine metabolism.
The force that opposes the flow of BLOOD through a vascular bed. It is equal to the difference in BLOOD PRESSURE across the vascular bed divided by the CARDIAC OUTPUT.
The circulation of the BLOOD through the LUNGS.
A group of compounds that contain the structure SO2NH2.
A coumarin that is used as an anticoagulant. Its actions and uses are similar to those of WARFARIN. (From Martindale, The Extra Pharmacopoeia, 30th ed, p233)
The short wide vessel arising from the conus arteriosus of the right ventricle and conveying unaerated blood to the lungs.
The blood pressure as recorded after wedging a CATHETER in a small PULMONARY ARTERY; believed to reflect the PRESSURE in the pulmonary CAPILLARIES.
The chemical and physical integrity of a pharmaceutical product.
Abnormalities in any part of the HEART SEPTUM resulting in abnormal communication between the left and the right chambers of the heart. The abnormal blood flow inside the heart may be caused by defects in the ATRIAL SEPTUM, the VENTRICULAR SEPTUM, or both.
Abnormal increase of resistance to blood flow within the hepatic PORTAL SYSTEM, frequently seen in LIVER CIRRHOSIS and conditions with obstruction of the PORTAL VEIN.
Chemistry dealing with the composition and preparation of agents having PHARMACOLOGIC ACTIONS or diagnostic use.
The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping.
Evaluation undertaken to assess the results or consequences of management and procedures used in combating disease in order to determine the efficacy, effectiveness, safety, and practicability of these interventions in individual cases or series.
Usually inert substances added to a prescription in order to provide suitable consistency to the dosage form. These include binders, matrix, base or diluent in pills, tablets, creams, salves, etc.
The transference of either one or both of the lungs from one human or animal to another.
Piperazines are a class of heterocyclic organic compounds containing a seven-membered ring with two nitrogen atoms at positions 1 and 4, often used in pharmaceuticals as smooth muscle relaxants, antipsychotics, antidepressants, and antihistamines, but can also be found as recreational drugs with stimulant and entactogen properties.
PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS.
A heterogeneous group of disorders, some hereditary, others acquired, characterized by abnormal structure or function of one or more of the elements of connective tissue, i.e., collagen, elastin, or the mucopolysaccharides.
Duration of blood flow after skin puncture. This test is used as a measure of capillary and platelet function.
A group of compounds derived from unsaturated 20-carbon fatty acids, primarily arachidonic acid, via the cyclooxygenase pathway. They are extremely potent mediators of a diverse group of physiological processes.
Therapy with two or more separate preparations given for a combined effect.
The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS.
The volume of BLOOD passing through the HEART per unit of time. It is usually expressed as liters (volume) per minute so as not to be confused with STROKE VOLUME (volume per beat).
The administration of drugs by the respiratory route. It includes insufflation into the respiratory tract.
Studies in which individuals or populations are followed to assess the outcome of exposures, procedures, or effects of a characteristic, e.g., occurrence of disease.
Injections made into a vein for therapeutic or experimental purposes.
Drugs or agents which antagonize or impair any mechanism leading to blood platelet aggregation, whether during the phases of activation and shape change or following the dense-granule release reaction and stimulation of the prostaglandin-thromboxane system.
The relationship between the dose of an administered drug and the response of the organism to the drug.
Azoles with an OXYGEN and a NITROGEN next to each other at the 1,2 positions, in contrast to OXAZOLES that have nitrogens at the 1,3 positions.
Cell surface receptors for EPOPROSTENOL. They are coupled to HETEROTRIMERIC G-PROTEINS.
Regional infusion of drugs via an arterial catheter. Often a pump is used to impel the drug through the catheter. Used in therapy of cancer, upper gastrointestinal hemorrhage, infection, and peripheral vascular disease.
Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience.
The hemodynamic and electrophysiological action of the right HEART VENTRICLE.
Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals.
Adenosine 5'-(trihydrogen diphosphate). An adenine nucleotide containing two phosphate groups esterified to the sugar moiety at the 5'-position.
Agents that prevent clotting.
Blocking of the PULMONARY ARTERY or one of its branches by an EMBOLUS.
The giving of drugs, chemicals, or other substances by mouth.
Radiography of blood vessels after injection of a contrast medium.
Studies used to test etiologic hypotheses in which inferences about an exposure to putative causal factors are derived from data relating to characteristics of persons under study or to events or experiences in their past. The essential feature is that some of the persons under study have the disease or outcome of interest and their characteristics are compared with those of unaffected persons.
## I'm sorry for any confusion, but "Japan" is not a medical term or concept. It is a country located in Asia, known as Nihon-koku or Nippon-koku in Japanese, and is renowned for its unique culture, advanced technology, and rich history. If you have any questions related to medical topics, I would be happy to help answer them!
The proportion of survivors in a group, e.g., of patients, studied and followed over a period, or the proportion of persons in a specified group alive at the beginning of a time interval who survive to the end of the interval. It is often studied using life table methods.

Characterization of the analgesic and anti-inflammatory activities of ketorolac and its enantiomers in the rat. (1/1891)

The marked analgesic efficacy of ketorolac in humans, relative to other nonsteroidal anti-inflammatory drugs (NSAIDs), has lead to speculation as to whether additional non-NSAID mechanism(s) contribute to its analgesic actions. To evaluate this possibility, we characterized (R,S)-ketorolac's pharmacological properties in vivo and in vitro using the nonselective cyclooxygenase (COX) inhibitors [indomethacin (INDO) and diclofenac sodium (DS)] as well as the selective COX-2 inhibitor, celecoxib, as references. The potency of racemic (R,S)-ketorolac was similar in tests of acetic acid-induced writhing, carrageenan-induced paw hyperalgesia, and carrageenan-induced edema formation in rats; ID50 values = 0.24, 0. 29, and 0.08 mg/kg, respectively. (R,S)-ketorolac's actions were stereospecific, with (S)-ketorolac possessing the biological activity of the racemate in the above tests. The analgesic potencies for (R,S)-, (S)-, and (R)-ketorolac, INDO, and DS were highly correlated with their anti-inflammatory potencies, suggesting a common mechanism. (R,S)-ketorolac was significantly more potent than INDO or DS in vivo. Neither difference in relative potency of COX inhibition for (R,S)-ketorolac over INDO and DS nor activity of (S)-ketorolac at a number of other enzymes, channels, or receptors could account for the differences in observed potency. The distribution coefficient for (R,S)-ketorolac was approximately 30-fold less than for DS or INDO, indicating that (R,S)-ketorolac is much less lipophilic than these NSAIDs. Therefore, the physicochemical and pharmacokinetics properties of (R,S)-ketorolac may optimize the concentrations of (S)-ketorolac at its biological target(s), resulting in greater efficacy and potency in vivo.  (+info)

Inhibition of endothelium-dependent hyperpolarization by endothelial prostanoids in guinea-pig coronary artery. (2/1891)

1. In smooth muscle of the circumflex coronary artery of guinea-pig, acetylcholine (ACh, 10(-6) M) produced an endothelium-dependent hyperpolarization consisting of two components. An initial component that occurs in the presence of ACh and a slow component that developed after ACh had been withdrawn. Each component of the hyperpolarization was accompanied by an increase in membrane conductance. 2. Indomethacin (5 x 10(-6) M) or diclofenac (10(-6) M), both inhibitors of cyclooxygenase, abolished only the slow hyperpolarization. The initial hyperpolarization was not inhibited by diclofenac nor by nitroarginine, an inhibitor of nitric oxide synthase. 3. Both components of the ACh-induced hyperpolarization were abolished in the presence of atropine (10(-6) M) or high-K solution ([K+]0 = 29.4 mM). 4. The interval between ACh-stimulation required to generate an initial hyperpolarization of reproducible amplitude was 20 min or greater, but it was reduced to less than 5 min after inhibiting cyclooxygenase activity. Conditioning stimulation of the artery with substance P (10(-7) M) also caused a long duration (about 20 min) inhibition of the ACh-response. 5. The amplitude of the hyperpolarization generated by Y-26763, a K+-channel opener, was reproducible within 10 min after withdrawal of ACh. 6. Exogenously applied prostacyclin (PGI2) hyperpolarized the membrane and reduced membrane resistance in concentrations over 2.8 x 10(-9)M. 7. At concentrations below threshold for hyperpolarization and when no alteration of membrane resistance occurred, PGI2 inhibited the initial component of the ACh-induced hyperpolarization. 8. It is concluded that endothelial prostanoids, possibly PGI2, have an inhibitory action on the release of endothelium-derived hyperpolarizing factor.  (+info)

The cyclo-oxygenase-dependent regulation of rabbit vein contraction: evidence for a prostaglandin E2-mediated relaxation. (3/1891)

1. Arachidonic acid (0.01-1 microM) induced relaxation of precontracted rings of rabbit saphenous vein, which was counteracted by contraction at concentrations higher than 1 microM. Concentrations higher than 1 microM were required to induce dose-dependent contraction of vena cava and thoracic aorta from the same animals. 2. Pretreatment with a TP receptor antagonist (GR32191B or SQ29548, 3 microM) potentiated the relaxant effect in the saphenous vein, revealed a vasorelaxant component in the vena cava response and did not affect the response of the aorta. 3. Removal of the endothelium from the venous rings, caused a 10 fold rightward shift in the concentration-relaxation curves to arachidonic acid. Whether or not the endothelium was present, the arachidonic acid-induced relaxations were prevented by indomethacin (10 microM) pretreatment. 4. In the saphenous vein, PGE2 was respectively a 50 and 100 fold more potent relaxant prostaglandin than PGI2 and PGD2. Pretreatment with the EP4 receptor antagonist, AH23848B, shifted the concentration-relaxation curves of this tissue to arachidonic acid in a dose-dependent manner. 5. In the presence of 1 microM arachidonic acid, venous rings produced 8-10 fold more PGE2 than did aorta whereas 6keto-PGF1alpha and TXB2 productions remained comparable. 6. Intact rings of saphenous vein relaxed in response to A23187. Pretreatment with L-NAME (100 microM) or indomethacin (10 microM) reduced this response by 50% whereas concomitant pretreatment totally suppressed it. After endothelium removal, the remaining relaxing response to A23187 was prevented by indomethacin but not affected by L-NAME. 7. We conclude that stimulation of the cyclo-oxygenase pathway by arachidonic acid induced endothelium-dependent, PGE2/EP4 mediated relaxation of the rabbit saphenous vein. This process might participate in the A23187-induced relaxation of the saphenous vein and account for a relaxing component in the response of the vena cava to arachidonic acid. It was not observed in thoracic aorta because of the lack of a vasodilatory receptor and/or the poorer ability of this tissue than veins to produce PGE2.  (+info)

Inhibition of nitric oxide but not prostacyclin prevents poststenotic dilatation in rabbit femoral artery. (4/1891)

BACKGROUND: Poststenotic dilatation (PSD) occurs in a low-pressure region where recirculation eddies oscillate in size during the cardiac cycle. NO may be an important mediator of PSD. METHODS AND RESULTS: Femoral arteries of 7 adult male New Zealand White rabbits were stenosed bilaterally to achieve a diameter reduction of 70. 9+/-6.7% (n=14). At the time of stenosis, the adventitia of one of the arteries was coated with 1 mmol/L of NG-nitro-L-arginine methyl ester (L-NAME) in 22% (wt/vol) Pluronic gel, while the contralateral vessel was coated with gel without L-NAME. In stenosed femoral arteries that were treated with gel without L-NAME, a maximum PSD of 30.99+/-7.92% (n=7) was observed in polymer casts at 3 days relative to the mean proximal diameter of 1.57+/-0.25 mm at a position 12 mm upstream of each stenosis. In contrast, the vessels treated with L-NAME exhibited a maximum PSD of only 7.16+/-8.81% (n=7) relative to the mean proximal diameter of 1.55+/-0.16 mm. L-NAME caused a 76. 9% reduction (P<0.001, n=7) of PSD. Similarly, NG-monomethyl-L-arginine 1 mmol/L and NG-nitro-L-arginine 10 micromol/L attenuated PSD by 57.5% (P<0.001, n=6) and 63.9% (P<0.05, n=6), respectively. Indomethacin 10 micromol/L caused no reduction in PSD. Arterial rings obtained from the poststenotic region were more sensitive and responsive to acetylcholine than those obtained proximal to the stenosis. CONCLUSIONS: NO, but not prostacyclin, is a major mediator of PSD.  (+info)

Effects of docosahexaenoic and eicosapentaenoic acid on lipid metabolism, eicosanoid production, platelet aggregation and atherosclerosis in hypercholesterolemic rats. (5/1891)

Exogenously hypercholesterolemic (ExHC) rats were fed on an atherogenic diet supplemented with 1% each of either ethyl ester docosahexaenoic acid [EE-DHA, 22:6(n-3)], ethyl ester eicosapentaenoic acid [EE-EPA, 20:5(n-3)] or safflower oil (SO) for 6 months. The rats fed on the diets containing EE-EPA or EE-DHA, compared with those fed on SO, had lower serum cholesterol and triacylglycerol levels, less aggregation of platelets and slower progress of intimal thickening in the ascending aorta. Relative to the SO-fed rats, both of the (n-3) fatty acid-fed rats had a significantly reduced proportion of arachidonic acid in the platelet and aortic phospholipids, and lower production of thromboxane A2 by platelets and of prostacyclin by the aorta. These results suggest that EPA and DHA are similarly involved in preventing atherosclerosis development by reducing hypercholesterolemia and modifying the platelet functions.  (+info)

Inhibition of effects of flow on potassium permeability in single perfused frog mesenteric capillaries. (6/1891)

1. We have investigated the effects of various potential inhibitors on flow-dependent K+ permeability (PK) of single perfused mesenteric microvessels in pithed frogs. 2. Neither superfusion with a nitric oxide synthase inhibitor, NG-monomethyl-L-arginine (10 or 100 micromol l-1), nor the addition of indomethacin (30 micromol l-1) to both perfusate and superfusate reduced the positive correlation between PK and flow velocity (U). 3. In the presence of agents known to raise intracellular levels of adenosine 3',5'-cyclic monophosphate (noradrenaline, 8-bromo-cAMP and a combination of forskolin and rolipram) the slope of the relation between PK and U was no longer significant, so that PK was no longer flow dependent. 4. These results confirm that the flow dependence of PK is a biological process and not an artefact of measurement and suggest a role for intracellular cAMP rather than nitric oxide or prostacyclin in the flow-dependent modulation of PK in frog mesenteric microvessels.  (+info)

Angiotensin II-induced constrictions are masked by bovine retinal vessels. (7/1891)

PURPOSE: To unmask the vasoconstricting effect of angiotensin II (Ang II) on retinal smooth muscle by studying its interaction with endothelium-derived paracrine substances. This study focused specifically on determining the changes in vascular diameter and the release of endothelial-derived vasodilators, nitric oxide (NO) and prostaglandin (PG) I2, from isolated retinal microvessels. METHODS: Bovine retinal central artery and vein were cannulated, and arterioles and venules were perfused with oxygenated/heparinized physiological salt solution at 37 degrees C. This ex vivo perfused retinal microcirculation model was used to observe the contractile effects of Ang II on arterioles and venules of different diameters. The NO and PGI2 synthase inhibitors, 1-NOARG and flurbiprofen, respectively, were used to unmask Ang II vasoconstriction; the changes in vascular diameters were then measured. Enzyme immunoassays were used to measure the release of cGMP (an index of NO release) and 6-keto-PG-F1alpha (a stable metabolite of PGI2) from isolated bovine retinal vessels. RESULTS: Topically applied Ang II (10(-10) M to 10(-4) M) caused significant (P < 0.05) arteriolar and venular constrictions in a dose-dependent manner, with the smallest retinal arterioles (7+/-0.2 microm luminal diameter) and venules (12+/-2 microm luminal diameter) significantly more sensitive than larger vessels. After the inhibition of endogenous NO and PGI2 synthesis by 1-NOARG and flurbiprofen, respectively, the vasoconstriction effects of Ang II became more pronounced. Again, the smallest vessels tested were significantly more sensitive, and synthesis of endothelial-derived relaxing factor (EDRF), therefore, may be most important in these vessels. Vasoactive doses of Ang II (10(-10) M to 10(-4) M) caused a dose-dependent increase in the release of NO and PGI2 from isolated bovine retinal vessels, indicating that the increase in EDRF may nullify direct Ang II-induced vasoconstriction. Interestingly, intraluminal administration of Ang II caused only vasodilation. CONCLUSIONS: This study demonstrates that the retinal vascular endothelium acts as a buffer against the vasoconstricting agent Ang II via release of vasodilators NO and PGI2, and the vasoconstriction effects due to Ang II are most prominent in the smallest diameter vessels.  (+info)

Vasodilator therapy for primary pulmonary hypertension in children. (8/1891)

BACKGROUND: This report presents 13 years of experience with vasodilator therapy for primary pulmonary hypertension (PPH) in children. Two eras were involved: between 1982 and 1987, oral calcium channel blockers were the only agents available for long-term therapy; after 1987, prostacyclin (PGI2) has been available for long-term intravenous use. METHODS AND RESULTS: Seventy-four children underwent short-term vasodilator testing with intravenous PGI2. Those who manifested pulmonary vasodilation ("acute responders") were treated with oral calcium channel blockers. Until 1987, "acute nonresponders" were treated in the same way as long as they had no serious side effects. When PGI2 became available for long-term administration, all nonresponders, as well as those who failed to improve clinically and hemodynamically on calcium channel blockers, were treated with long-term PGI2. In the 31 responders, calcium channel blockers improved survival compared with the 43 nonresponders (P=0.0002). Survival was also better in 24 PGI2-treated nonresponders compared with 22 nonresponders for whom PGI2 was unavailable (P=0.0005) as well as in all children who failed conventional therapy (n=31; P=0.002). CONCLUSIONS: Long-term vasodilator therapy improves survival in children with PPH. In acute responders, oral calcium channel blockers generally suffice. In both nonresponders to short-term testing and responders who fail to improve on calcium channel blockers, continuous intravenous infusion of PGI2 improves survival.  (+info)

Epoprostenol is a medication that belongs to a class of drugs called prostaglandins. It is a synthetic analog of a natural substance in the body called prostacyclin, which widens blood vessels and has anti-platelet effects. Epoprostenol is used to treat pulmonary arterial hypertension (PAH), a condition characterized by high blood pressure in the arteries that supply blood to the lungs.

Epoprostenol works by relaxing the smooth muscle in the walls of the pulmonary arteries, which reduces the resistance to blood flow and lowers the pressure within these vessels. This helps improve symptoms such as shortness of breath, fatigue, and chest pain, and can also prolong survival in people with PAH.

Epoprostenol is administered continuously through a small pump that delivers the medication directly into the bloodstream. It is a potent vasodilator, which means it can cause a sudden drop in blood pressure if not given carefully. Therefore, it is usually started in a hospital setting under close medical supervision.

Common side effects of epoprostenol include headache, flushing, jaw pain, nausea, vomiting, diarrhea, and muscle or joint pain. More serious side effects can include bleeding, infection at the site of the catheter, and an allergic reaction to the medication.

Pulmonary hypertension is a medical condition characterized by increased blood pressure in the pulmonary arteries, which are the blood vessels that carry blood from the right side of the heart to the lungs. This results in higher than normal pressures in the pulmonary circulation and can lead to various symptoms and complications.

Pulmonary hypertension is typically defined as a mean pulmonary artery pressure (mPAP) greater than or equal to 25 mmHg at rest, as measured by right heart catheterization. The World Health Organization (WHO) classifies pulmonary hypertension into five groups based on the underlying cause:

1. Pulmonary arterial hypertension (PAH): This group includes idiopathic PAH, heritable PAH, drug-induced PAH, and associated PAH due to conditions such as connective tissue diseases, HIV infection, portal hypertension, congenital heart disease, and schistosomiasis.
2. Pulmonary hypertension due to left heart disease: This group includes conditions that cause elevated left atrial pressure, such as left ventricular systolic or diastolic dysfunction, valvular heart disease, and congenital cardiovascular shunts.
3. Pulmonary hypertension due to lung diseases and/or hypoxia: This group includes chronic obstructive pulmonary disease (COPD), interstitial lung disease, sleep-disordered breathing, alveolar hypoventilation disorders, and high altitude exposure.
4. Chronic thromboembolic pulmonary hypertension (CTEPH): This group includes persistent obstruction of the pulmonary arteries due to organized thrombi or emboli.
5. Pulmonary hypertension with unclear and/or multifactorial mechanisms: This group includes hematologic disorders, systemic disorders, metabolic disorders, and other conditions that can cause pulmonary hypertension but do not fit into the previous groups.

Symptoms of pulmonary hypertension may include shortness of breath, fatigue, chest pain, lightheadedness, and syncope (fainting). Diagnosis typically involves a combination of medical history, physical examination, imaging studies, and invasive testing such as right heart catheterization. Treatment depends on the underlying cause but may include medications, oxygen therapy, pulmonary rehabilitation, and, in some cases, surgical intervention.

Antihypertensive agents are a class of medications used to treat high blood pressure (hypertension). They work by reducing the force and rate of heart contractions, dilating blood vessels, or altering neurohormonal activation to lower blood pressure. Examples include diuretics, beta blockers, ACE inhibitors, ARBs, calcium channel blockers, and direct vasodilators. These medications may be used alone or in combination to achieve optimal blood pressure control.

"Drug storage" refers to the proper handling, maintenance, and preservation of medications in a safe and suitable environment to ensure their effectiveness and safety until they are used. Proper drug storage includes:

1. Protecting drugs from light, heat, and moisture: Exposure to these elements can degrade the quality and potency of medications. Therefore, it is recommended to store most drugs in a cool, dry place, away from direct sunlight.

2. Keeping drugs out of reach of children and pets: Medications should be stored in a secure location, such as a locked cabinet or medicine chest, to prevent accidental ingestion or harm to young children and animals.

3. Following storage instructions on drug labels and packaging: Some medications require specific storage conditions, such as refrigeration or protection from freezing. Always follow the storage instructions provided by the manufacturer or pharmacist.

4. Regularly inspecting drugs for signs of degradation or expiration: Check medications for changes in color, consistency, or odor, and discard any that have expired or show signs of spoilage.

5. Storing drugs separately from one another: Keep different medications separate to prevent cross-contamination, incorrect dosing, or accidental mixing of incompatible substances.

6. Avoiding storage in areas with high humidity or temperature fluctuations: Bathrooms, kitchens, and garages are generally not ideal for storing medications due to their exposure to moisture, heat, and temperature changes.

Proper drug storage is crucial for maintaining the safety, efficacy, and stability of medications. Improper storage can lead to reduced potency, increased risk of adverse effects, or even life-threatening situations. Always consult a healthcare professional or pharmacist for specific storage instructions and recommendations.

Iloprost is a synthetic analogue of prostacyclin, a naturally occurring substance in the body. It is a medication that belongs to a class of drugs called vasodilators, which work by relaxing and widening blood vessels. Iloprost is used to treat pulmonary arterial hypertension (PAH), a condition characterized by high blood pressure in the arteries that supply blood to the lungs. By dilating these blood vessels, iloprost helps reduce the workload on the heart and improve symptoms associated with PAH such as shortness of breath, fatigue, and dizziness.

Iloprost is administered through inhalation using a nebulizer, typically several times a day. It may also be used to prevent or treat episodes of digital ischemia, a condition that causes reduced blood flow to the fingers and toes, leading to pain and tissue damage.

It's important to note that while iloprost can help manage symptoms of PAH and digital ischemia, it does not cure these conditions. Close monitoring by a healthcare provider is necessary to ensure safe and effective use of this medication.

Intravenous (IV) infusion is a medical procedure in which liquids, such as medications, nutrients, or fluids, are delivered directly into a patient's vein through a needle or a catheter. This route of administration allows for rapid absorption and distribution of the infused substance throughout the body. IV infusions can be used for various purposes, including resuscitation, hydration, nutrition support, medication delivery, and blood product transfusion. The rate and volume of the infusion are carefully controlled to ensure patient safety and efficacy of treatment.

Intravenous (IV) administration is a medical procedure where medication or fluids are delivered directly into a vein. This method allows for rapid absorption and distribution of the substance throughout the body. It is commonly used to provide immediate treatment in emergency situations, administer medications that cannot be given by other routes, or deliver fluids and electrolytes when someone is dehydrated.

To perform an IV administration, a healthcare professional first prepares the necessary equipment, including a sterile needle or catheter, syringe, and the medication or fluid to be administered. The site of insertion is typically on the back of the hand, inner elbow, or forearm, where veins are more visible and accessible. After cleaning and disinfecting the skin, the healthcare professional inserts the needle or catheter into the vein, securing it in place with tape or a dressing. The medication or fluid is then slowly injected or infused through the IV line.

Possible risks associated with IV administration include infection, infiltration (when the fluid leaks into surrounding tissue instead of the vein), extravasation (when the medication leaks out of the vein and causes tissue damage), and phlebitis (inflammation of the vein). Proper technique and monitoring during and after IV administration can help minimize these risks.

Pulmonary Veno-Occlusive Disease (PVOD) is a rare form of pulmonary hypertension, characterized by the obstruction or blockage of the pulmonary veins. This obstruction can lead to increased pressure in the pulmonary circulation, ultimately causing right heart failure.

The medical definition of Pulmonary Veno-Occlusive Disease is: "A progressive and often fatal condition in which there is a selective occlusion or obliteration of the pulmonary venules and small veins, resulting in pulmonary hypertension, right ventricular failure, and death."

The obstruction of the pulmonary veins can be caused by various factors, including inflammation, fibrosis, or thrombosis. Symptoms of PVOD may include shortness of breath, fatigue, coughing up blood, and signs of right heart failure such as peripheral edema and ascites.

Diagnosis of PVOD can be challenging due to its rarity and nonspecific symptoms. Imaging studies, such as chest X-ray or CT scan, may show signs of pulmonary congestion and enlarged central pulmonary veins. A definitive diagnosis usually requires a lung biopsy.

Treatment options for PVOD are limited, and there is no cure for the disease. Currently, lung transplantation remains the only potentially curative treatment option for patients with PVOD.

Hemodynamics is the study of how blood flows through the cardiovascular system, including the heart and the vascular network. It examines various factors that affect blood flow, such as blood volume, viscosity, vessel length and diameter, and pressure differences between different parts of the circulatory system. Hemodynamics also considers the impact of various physiological and pathological conditions on these variables, and how they in turn influence the function of vital organs and systems in the body. It is a critical area of study in fields such as cardiology, anesthesiology, and critical care medicine.

Tolazoline is a medication that acts as an alpha-adrenergic antagonist and a weak peripheral vasodilator. It is primarily used in the treatment of digital ischemia, which is a lack of blood flow to the fingers or toes, often caused by diseases such as scleroderma or Raynaud's phenomenon. Tolazoline works by relaxing the blood vessels and improving blood flow to the affected areas.

It is important to note that the use of tolazoline is limited due to its potential for causing serious side effects, including hypotension (low blood pressure), tachycardia (rapid heart rate), and cardiac arrhythmias (irregular heart rhythms). Therefore, it should only be used under the close supervision of a healthcare provider.

Exercise tolerance is a term used to describe the ability of an individual to perform physical activity or exercise without experiencing symptoms such as shortness of breath, chest pain, or undue fatigue. It is often used as a measure of cardiovascular fitness and can be assessed through various tests, such as a stress test or a six-minute walk test. Exercise intolerance may indicate the presence of underlying medical conditions, such as heart disease, lung disease, or deconditioning.

Pharmaceutical preservatives are substances that are added to medications, pharmaceutical products, or biological specimens to prevent degradation, contamination, or spoilage caused by microbial growth, chemical reactions, or environmental factors. These preservatives help extend the shelf life and ensure the stability, safety, and efficacy of the pharmaceutical formulation during storage and use.

Commonly used pharmaceutical preservatives include:

1. Antimicrobials: These are further classified into antifungals (e.g., benzalkonium chloride, chlorhexidine, thimerosal), antibacterials (e.g., parabens, phenol, benzyl alcohol), and antivirals (e.g., phenolic compounds). They work by inhibiting the growth of microorganisms like bacteria, fungi, and viruses.
2. Antioxidants: These substances prevent or slow down oxidation reactions that can degrade pharmaceutical products. Examples include ascorbic acid (vitamin C), tocopherols (vitamin E), sulfites, and butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT).
3. Chelating agents: These bind to metal ions that can catalyze degradation reactions in pharmaceutical products. Ethylenediaminetetraacetic acid (EDTA) is an example of a chelating agent used in pharmaceuticals.

The choice of preservative depends on the type of formulation, route of administration, and desired shelf life. The concentration of the preservative should be optimized to maintain product stability while minimizing potential toxicity or adverse effects. It is essential to conduct thorough safety and compatibility studies before incorporating any preservative into a pharmaceutical formulation.

Sulfones are a group of medications that contain a sulfur atom bonded to two oxygen atoms and one other group, typically a hydrogen or carbon atom. They have various medical uses, including as antibacterial, antifungal, and anti-inflammatory agents. One example of a sulfone is dapsone, which is used to treat bacterial infections such as leprosy and Pneumocystis jirovecii pneumonia (PJP), as well as some inflammatory skin conditions. It's important to note that sulfones can have significant side effects and should only be used under the supervision of a healthcare professional.

A capillary hemangioma is a benign (non-cancerous) vascular tumor that is made up of an overgrowth of small blood vessels called capillaries. These lesions are quite common and usually appear during the first few weeks or months of life, although they can also develop later in childhood or even in adulthood.

Capillary hemangiomas typically appear as a bright red, raised, and rubbery lesion on the skin. They may be small and localized, or they can grow and spread to cover a larger area of the body. In some cases, capillary hemangiomas may also form on internal organs such as the liver, brain, or gastrointestinal tract.

While capillary hemangiomas are generally harmless, they can cause cosmetic concerns if they appear on the face or other visible areas of the body. In some cases, these lesions may also interfere with vision, hearing, or other bodily functions if they grow too large or are located in sensitive areas.

Most capillary hemangiomas will eventually shrink and disappear on their own over time, typically within the first few years of life. However, in some cases, medical treatment may be necessary to help speed up this process or to address any complications that arise. Treatment options for capillary hemangiomas may include medications such as corticosteroids or beta-blockers, laser therapy, or surgical removal.

Vasodilator agents are pharmacological substances that cause the relaxation or widening of blood vessels by relaxing the smooth muscle in the vessel walls. This results in an increase in the diameter of the blood vessels, which decreases vascular resistance and ultimately reduces blood pressure. Vasodilators can be further classified based on their site of action:

1. Systemic vasodilators: These agents cause a generalized relaxation of the smooth muscle in the walls of both arteries and veins, resulting in a decrease in peripheral vascular resistance and preload (the volume of blood returning to the heart). Examples include nitroglycerin, hydralazine, and calcium channel blockers.
2. Arterial vasodilators: These agents primarily affect the smooth muscle in arterial vessel walls, leading to a reduction in afterload (the pressure against which the heart pumps blood). Examples include angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), and direct vasodilators like sodium nitroprusside.
3. Venous vasodilators: These agents primarily affect the smooth muscle in venous vessel walls, increasing venous capacitance and reducing preload. Examples include nitroglycerin and other organic nitrates.

Vasodilator agents are used to treat various cardiovascular conditions such as hypertension, heart failure, angina, and pulmonary arterial hypertension. It is essential to monitor their use carefully, as excessive vasodilation can lead to orthostatic hypotension, reflex tachycardia, or fluid retention.

Heart-lung transplantation is a surgical procedure where both the heart and lungs of a patient are replaced with those from a deceased donor. This complex and highly specialized surgery is typically considered as a last resort for patients suffering from end-stage lung or heart-lung diseases, such as cystic fibrosis, pulmonary fibrosis, chronic obstructive pulmonary disease (COPD), or certain forms of congenital heart disease, who have exhausted all other treatment options and face imminent death.

The procedure involves removing the patient's diseased heart and lungs en bloc, followed by implanting the donor's heart and lungs in their place. The surgery requires a skilled multidisciplinary team of cardiothoracic surgeons, anesthesiologists, perfusionists, transplant coordinators, and intensive care specialists.

Following the transplantation, patients require lifelong immunosuppressive therapy to prevent rejection of the transplanted organs. Despite the significant risks associated with this procedure, including infection, bleeding, and rejection, heart-lung transplantation can significantly improve both survival and quality of life for carefully selected patients with advanced heart-lung disease.

Purines are heterocyclic aromatic organic compounds that consist of a pyrimidine ring fused to an imidazole ring. They are fundamental components of nucleotides, which are the building blocks of DNA and RNA. In the body, purines can be synthesized endogenously or obtained through dietary sources such as meat, seafood, and certain vegetables.

Once purines are metabolized, they are broken down into uric acid, which is excreted by the kidneys. Elevated levels of uric acid in the body can lead to the formation of uric acid crystals, resulting in conditions such as gout or kidney stones. Therefore, maintaining a balanced intake of purine-rich foods and ensuring proper kidney function are essential for overall health.

Vascular resistance is a measure of the opposition to blood flow within a vessel or a group of vessels, typically expressed in units of mmHg/(mL/min) or sometimes as dynes*sec/cm^5. It is determined by the diameter and length of the vessels, as well as the viscosity of the blood flowing through them. In general, a decrease in vessel diameter, an increase in vessel length, or an increase in blood viscosity will result in an increase in vascular resistance, while an increase in vessel diameter, a decrease in vessel length, or a decrease in blood viscosity will result in a decrease in vascular resistance. Vascular resistance is an important concept in the study of circulation and cardiovascular physiology because it plays a key role in determining blood pressure and blood flow within the body.

Pulmonary circulation refers to the process of blood flow through the lungs, where blood picks up oxygen and releases carbon dioxide. This is a vital part of the overall circulatory system, which delivers nutrients and oxygen to the body's cells while removing waste products like carbon dioxide.

In pulmonary circulation, deoxygenated blood from the systemic circulation returns to the right atrium of the heart via the superior and inferior vena cava. The blood then moves into the right ventricle through the tricuspid valve and gets pumped into the pulmonary artery when the right ventricle contracts.

The pulmonary artery divides into smaller vessels called arterioles, which further branch into a vast network of tiny capillaries in the lungs. Here, oxygen from the alveoli diffuses into the blood, binding to hemoglobin in red blood cells, while carbon dioxide leaves the blood and is exhaled through the nose or mouth.

The now oxygenated blood collects in venules, which merge to form pulmonary veins. These veins transport the oxygen-rich blood back to the left atrium of the heart, where it enters the systemic circulation once again. This continuous cycle enables the body's cells to receive the necessary oxygen and nutrients for proper functioning while disposing of waste products.

Sulfonamides are a group of synthetic antibacterial drugs that contain the sulfonamide group (SO2NH2) in their chemical structure. They are bacteriostatic agents, meaning they inhibit bacterial growth rather than killing them outright. Sulfonamides work by preventing the bacteria from synthesizing folic acid, which is essential for their survival.

The first sulfonamide drug was introduced in the 1930s and since then, many different sulfonamides have been developed with varying chemical structures and pharmacological properties. They are used to treat a wide range of bacterial infections, including urinary tract infections, respiratory tract infections, skin and soft tissue infections, and ear infections.

Some common sulfonamide drugs include sulfisoxazole, sulfamethoxazole, and trimethoprim-sulfamethoxazole (a combination of a sulfonamide and another antibiotic called trimethoprim). While sulfonamides are generally safe and effective when used as directed, they can cause side effects such as rash, nausea, and allergic reactions. It is important to follow the prescribing physician's instructions carefully and to report any unusual symptoms or side effects promptly.

Acenocoumarol is an anticoagulant medication that is used to prevent and treat blood clots. It works by inhibiting the formation of vitamin K-dependent clotting factors, which are necessary for normal blood coagulation. This results in a prolonged bleeding time and reduced risk of blood clots.

Acenocoumarol is a coumarin derivative and is available under various brand names, including Sintrom and Nicoumalone. It is typically administered orally in the form of tablets and its effects are monitored through regular blood tests to ensure that the dosage is appropriate and that the risk of bleeding complications is minimized.

Common side effects of acenocoumarol include easy bruising, nosebleeds, and skin rashes. It may also interact with a variety of other medications, including antibiotics, antifungals, and certain herbal supplements, so it is important to inform your healthcare provider of all medications and supplements you are taking before starting acenocoumarol therapy.

It is important to note that acenocoumarol has a narrow therapeutic index, meaning that the difference between an effective dose and a toxic dose is relatively small. Therefore, it is essential to follow your healthcare provider's instructions carefully when taking this medication and to have regular blood tests to monitor its effects on your coagulation status.

The pulmonary artery is a large blood vessel that carries deoxygenated blood from the right ventricle of the heart to the lungs for oxygenation. It divides into two main branches, the right and left pulmonary arteries, which further divide into smaller vessels called arterioles, and then into a vast network of capillaries in the lungs where gas exchange occurs. The thin walls of these capillaries allow oxygen to diffuse into the blood and carbon dioxide to diffuse out, making the blood oxygen-rich before it is pumped back to the left side of the heart through the pulmonary veins. This process is crucial for maintaining proper oxygenation of the body's tissues and organs.

Pulmonary wedge pressure, also known as pulmonary capillary wedge pressure (PCWP) or left heart filling pressure, is a measurement obtained during right heart catheterization. It reflects the pressure in the left atrium, which is an estimate of the diastolic pressure in the left ventricle. Normal PCWP ranges from 4 to 12 mmHg. Increased pulmonary wedge pressure can indicate heart failure or other cardiac disorders that affect the left side of the heart.

Drug stability refers to the ability of a pharmaceutical drug product to maintain its physical, chemical, and biological properties during storage and use, under specified conditions. A stable drug product retains its desired quality, purity, strength, and performance throughout its shelf life. Factors that can affect drug stability include temperature, humidity, light exposure, and container compatibility. Maintaining drug stability is crucial to ensure the safety and efficacy of medications for patients.

A heart septal defect is a type of congenital heart defect, which means it is present at birth. It involves an abnormal opening in the septum, the wall that separates the two sides of the heart. This opening allows oxygen-rich blood to leak into the oxygen-poor blood chambers in the heart.

There are several types of heart septal defects, including:

1. Atrial Septal Defect (ASD): A hole in the atrial septum, the wall between the two upper chambers of the heart (the right and left atria).
2. Ventricular Septal Defect (VSD): A hole in the ventricular septum, the wall between the two lower chambers of the heart (the right and left ventricles).
3. Atrioventricular Septal Defect (AVSD): A combination of an ASD and a VSD, often accompanied by malformation of the mitral and/or tricuspid valves.

The severity of a heart septal defect depends on the size of the opening and its location in the septum. Small defects may cause no symptoms and may close on their own over time. Larger defects can lead to complications, such as heart failure, pulmonary hypertension, or infective endocarditis, and may require medical or surgical intervention.

Portal hypertension is a medical condition characterized by an increased pressure in the portal vein, which is the large blood vessel that carries blood from the intestines, spleen, and pancreas to the liver. Normal portal venous pressure is approximately 5-10 mmHg. Portal hypertension is defined as a portal venous pressure greater than 10 mmHg.

The most common cause of portal hypertension is cirrhosis of the liver, which leads to scarring and narrowing of the small blood vessels in the liver, resulting in increased resistance to blood flow. Other causes include blood clots in the portal vein, inflammation of the liver or bile ducts, and invasive tumors that block the flow of blood through the liver.

Portal hypertension can lead to a number of complications, including the development of abnormal blood vessels (varices) in the esophagus, stomach, and intestines, which are prone to bleeding. Ascites, or the accumulation of fluid in the abdominal cavity, is another common complication of portal hypertension. Other potential complications include encephalopathy, which is a condition characterized by confusion, disorientation, and other neurological symptoms, and an increased risk of bacterial infections.

Treatment of portal hypertension depends on the underlying cause and the severity of the condition. Medications to reduce pressure in the portal vein, such as beta blockers or nitrates, may be used. Endoscopic procedures to band or inject varices can help prevent bleeding. In severe cases, surgery or liver transplantation may be necessary.

Pharmaceutical chemistry is a branch of chemistry that deals with the design, synthesis, and development of chemical entities used as medications. It involves the study of drugs' physical, chemical, and biological properties, as well as their interactions with living organisms. This field also encompasses understanding the absorption, distribution, metabolism, and excretion (ADME) of drugs in the body, which are critical factors in drug design and development. Pharmaceutical chemists often work closely with biologists, medical professionals, and engineers to develop new medications and improve existing ones.

Parenteral infusions refer to the administration of fluids or medications directly into a patient's vein or subcutaneous tissue using a needle or catheter. This route bypasses the gastrointestinal tract and allows for rapid absorption and onset of action. Parenteral infusions can be used to correct fluid and electrolyte imbalances, administer medications that cannot be given orally, provide nutritional support, and deliver blood products. Common types of parenteral infusions include intravenous (IV) drips, IV push, and subcutaneous infusions. It is important that parenteral infusions are administered using aseptic technique to reduce the risk of infection.

Treatment outcome is a term used to describe the result or effect of medical treatment on a patient's health status. It can be measured in various ways, such as through symptoms improvement, disease remission, reduced disability, improved quality of life, or survival rates. The treatment outcome helps healthcare providers evaluate the effectiveness of a particular treatment plan and make informed decisions about future care. It is also used in clinical research to compare the efficacy of different treatments and improve patient care.

Excipients are inactive substances that serve as vehicles or mediums for the active ingredients in medications. They make up the bulk of a pharmaceutical formulation and help to stabilize, preserve, and enhance the delivery of the active drug compound. Common examples of excipients include binders, fillers, coatings, disintegrants, flavors, sweeteners, and colors. While excipients are generally considered safe and inert, they can sometimes cause allergic reactions or other adverse effects in certain individuals.

Lung transplantation is a surgical procedure where one or both diseased lungs are removed and replaced with healthy lungs from a deceased donor. It is typically considered as a treatment option for patients with end-stage lung diseases, such as chronic obstructive pulmonary disease (COPD), cystic fibrosis, idiopathic pulmonary fibrosis, and alpha-1 antitrypsin deficiency, who have exhausted all other medical treatments and continue to suffer from severe respiratory failure.

The procedure involves several steps, including evaluating the patient's eligibility for transplantation, matching the donor's lung size and blood type with the recipient, and performing the surgery under general anesthesia. After the surgery, patients require close monitoring and lifelong immunosuppressive therapy to prevent rejection of the new lungs.

Lung transplantation can significantly improve the quality of life and survival rates for some patients with end-stage lung disease, but it is not without risks, including infection, bleeding, and rejection. Therefore, careful consideration and thorough evaluation are necessary before pursuing this treatment option.

Piperazines are a class of heterocyclic organic compounds that contain a seven-membered ring with two nitrogen atoms at positions 1 and 4. They have the molecular formula N-NRR' where R and R' can be alkyl or aryl groups. Piperazines have a wide range of uses in pharmaceuticals, agrochemicals, and as building blocks in organic synthesis.

In a medical context, piperazines are used in the manufacture of various drugs, including some antipsychotics, antidepressants, antihistamines, and anti-worm medications. For example, the antipsychotic drug trifluoperazine and the antidepressant drug nefazodone both contain a piperazine ring in their chemical structure.

However, it's important to note that some piperazines are also used as recreational drugs due to their stimulant and euphoric effects. These include compounds such as BZP (benzylpiperazine) and TFMPP (trifluoromethylphenylpiperazine), which have been linked to serious health risks, including addiction, seizures, and death. Therefore, the use of these substances should be avoided.

Blood pressure is the force exerted by circulating blood on the walls of the blood vessels. It is measured in millimeters of mercury (mmHg) and is given as two figures:

1. Systolic pressure: This is the pressure when the heart pushes blood out into the arteries.
2. Diastolic pressure: This is the pressure when the heart rests between beats, allowing it to fill with blood.

Normal blood pressure for adults is typically around 120/80 mmHg, although this can vary slightly depending on age, sex, and other factors. High blood pressure (hypertension) is generally considered to be a reading of 130/80 mmHg or higher, while low blood pressure (hypotension) is usually defined as a reading below 90/60 mmHg. It's important to note that blood pressure can fluctuate throughout the day and may be affected by factors such as stress, physical activity, and medication use.

Connective tissue diseases (CTDs) are a group of disorders that involve the abnormal production and accumulation of abnormal connective tissues in various parts of the body. Connective tissues are the structural materials that support and bind other tissues and organs together. They include tendons, ligaments, cartilage, fat, and the material that fills the spaces between cells, called the extracellular matrix.

Connective tissue diseases can affect many different systems in the body, including the skin, joints, muscles, lungs, kidneys, gastrointestinal tract, and blood vessels. Some CTDs are autoimmune disorders, meaning that the immune system mistakenly attacks healthy connective tissues. Others may be caused by genetic mutations or environmental factors.

Some examples of connective tissue diseases include:

* Systemic lupus erythematosus (SLE)
* Rheumatoid arthritis (RA)
* Scleroderma
* Dermatomyositis/Polymyositis
* Mixed Connective Tissue Disease (MCTD)
* Sjogren's syndrome
* Ehlers-Danlos syndrome
* Marfan syndrome
* Osteogenesis imperfecta

The specific symptoms and treatment of connective tissue diseases vary depending on the type and severity of the condition. Treatment may include medications to reduce inflammation, suppress the immune system, or manage pain. In some cases, surgery may be necessary to repair or replace damaged tissues or organs.

Bleeding time is a medical test that measures the time it takes for a small blood vessel to stop bleeding after being cut. It's used to evaluate platelet function and the effectiveness of blood clotting. The most common method used to measure bleeding time is the Ivy method, which involves making a standardized incision on the forearm and measuring the time it takes for the bleeding to stop. A normal bleeding time ranges from 2 to 9 minutes, but this can vary depending on the specific method used. Prolonged bleeding time may indicate an impairment in platelet function or clotting factor deficiency.

Prostaglandins are naturally occurring, lipid-derived hormones that play various important roles in the human body. They are produced in nearly every tissue in response to injury or infection, and they have diverse effects depending on the site of release and the type of prostaglandin. Some of their functions include:

1. Regulation of inflammation: Prostaglandins contribute to the inflammatory response by increasing vasodilation, promoting fluid accumulation, and sensitizing pain receptors, which can lead to symptoms such as redness, heat, swelling, and pain.
2. Modulation of gastrointestinal functions: Prostaglandins protect the stomach lining from acid secretion and promote mucus production, maintaining the integrity of the gastric mucosa. They also regulate intestinal motility and secretion.
3. Control of renal function: Prostaglandins help regulate blood flow to the kidneys, maintain sodium balance, and control renin release, which affects blood pressure and fluid balance.
4. Regulation of smooth muscle contraction: Prostaglandins can cause both relaxation and contraction of smooth muscles in various tissues, such as the uterus, bronchioles, and vascular system.
5. Modulation of platelet aggregation: Some prostaglandins inhibit platelet aggregation, preventing blood clots from forming too quickly or becoming too large.
6. Reproductive system regulation: Prostaglandins are involved in the menstrual cycle, ovulation, and labor induction by promoting uterine contractions.
7. Neurotransmission: Prostaglandins can modulate neurotransmitter release and neuronal excitability, affecting pain perception, mood, and cognition.

Prostaglandins exert their effects through specific G protein-coupled receptors (GPCRs) found on the surface of target cells. There are several distinct types of prostaglandins (PGs), including PGD2, PGE2, PGF2α, PGI2 (prostacyclin), and thromboxane A2 (TXA2). Each type has unique functions and acts through specific receptors. Prostaglandins are synthesized from arachidonic acid, a polyunsaturated fatty acid derived from membrane phospholipids, by the action of cyclooxygenase (COX) enzymes. Nonsteroidal anti-inflammatory drugs (NSAIDs), such as aspirin and ibuprofen, inhibit COX activity, reducing prostaglandin synthesis and providing analgesic, anti-inflammatory, and antipyretic effects.

Combination drug therapy is a treatment approach that involves the use of multiple medications with different mechanisms of action to achieve better therapeutic outcomes. This approach is often used in the management of complex medical conditions such as cancer, HIV/AIDS, and cardiovascular diseases. The goal of combination drug therapy is to improve efficacy, reduce the risk of drug resistance, decrease the likelihood of adverse effects, and enhance the overall quality of life for patients.

In combining drugs, healthcare providers aim to target various pathways involved in the disease process, which may help to:

1. Increase the effectiveness of treatment by attacking the disease from multiple angles.
2. Decrease the dosage of individual medications, reducing the risk and severity of side effects.
3. Slow down or prevent the development of drug resistance, a common problem in chronic diseases like HIV/AIDS and cancer.
4. Improve patient compliance by simplifying dosing schedules and reducing pill burden.

Examples of combination drug therapy include:

1. Antiretroviral therapy (ART) for HIV treatment, which typically involves three or more drugs from different classes to suppress viral replication and prevent the development of drug resistance.
2. Chemotherapy regimens for cancer treatment, where multiple cytotoxic agents are used to target various stages of the cell cycle and reduce the likelihood of tumor cells developing resistance.
3. Cardiovascular disease management, which may involve combining medications such as angiotensin-converting enzyme (ACE) inhibitors, beta-blockers, diuretics, and statins to control blood pressure, heart rate, fluid balance, and cholesterol levels.
4. Treatment of tuberculosis, which often involves a combination of several antibiotics to target different aspects of the bacterial life cycle and prevent the development of drug-resistant strains.

When prescribing combination drug therapy, healthcare providers must carefully consider factors such as potential drug interactions, dosing schedules, adverse effects, and contraindications to ensure safe and effective treatment. Regular monitoring of patients is essential to assess treatment response, manage side effects, and adjust the treatment plan as needed.

Platelet aggregation is the clumping together of platelets (thrombocytes) in the blood, which is an essential step in the process of hemostasis (the stopping of bleeding) after injury to a blood vessel. When the inner lining of a blood vessel is damaged, exposure of subendothelial collagen and tissue factor triggers platelet activation. Activated platelets change shape, become sticky, and release the contents of their granules, which include ADP (adenosine diphosphate).

ADP then acts as a chemical mediator to attract and bind additional platelets to the site of injury, leading to platelet aggregation. This forms a plug that seals the damaged vessel and prevents further blood loss. Platelet aggregation is also a crucial component in the formation of blood clots (thrombosis) within blood vessels, which can have pathological consequences such as heart attacks and strokes if they obstruct blood flow to vital organs.

Cardiac output is a measure of the amount of blood that is pumped by the heart in one minute. It is defined as the product of stroke volume (the amount of blood pumped by the left ventricle during each contraction) and heart rate (the number of contractions per minute). Normal cardiac output at rest for an average-sized adult is about 5 to 6 liters per minute. Cardiac output can be increased during exercise or other conditions that require more blood flow, such as during illness or injury. It can be measured noninvasively using techniques such as echocardiography or invasively through a catheter placed in the heart.

"Inhalation administration" is a medical term that refers to the method of delivering medications or therapeutic agents directly into the lungs by inhaling them through the airways. This route of administration is commonly used for treating respiratory conditions such as asthma, COPD (chronic obstructive pulmonary disease), and cystic fibrosis.

Inhalation administration can be achieved using various devices, including metered-dose inhalers (MDIs), dry powder inhalers (DPIs), nebulizers, and soft-mist inhalers. Each device has its unique mechanism of delivering the medication into the lungs, but they all aim to provide a high concentration of the drug directly to the site of action while minimizing systemic exposure and side effects.

The advantages of inhalation administration include rapid onset of action, increased local drug concentration, reduced systemic side effects, and improved patient compliance due to the ease of use and non-invasive nature of the delivery method. However, proper technique and device usage are crucial for effective therapy, as incorrect usage may result in suboptimal drug deposition and therapeutic outcomes.

Follow-up studies are a type of longitudinal research that involve repeated observations or measurements of the same variables over a period of time, in order to understand their long-term effects or outcomes. In medical context, follow-up studies are often used to evaluate the safety and efficacy of medical treatments, interventions, or procedures.

In a typical follow-up study, a group of individuals (called a cohort) who have received a particular treatment or intervention are identified and then followed over time through periodic assessments or data collection. The data collected may include information on clinical outcomes, adverse events, changes in symptoms or functional status, and other relevant measures.

The results of follow-up studies can provide important insights into the long-term benefits and risks of medical interventions, as well as help to identify factors that may influence treatment effectiveness or patient outcomes. However, it is important to note that follow-up studies can be subject to various biases and limitations, such as loss to follow-up, recall bias, and changes in clinical practice over time, which must be carefully considered when interpreting the results.

Intravenous injections are a type of medical procedure where medication or fluids are administered directly into a vein using a needle and syringe. This route of administration is also known as an IV injection. The solution injected enters the patient's bloodstream immediately, allowing for rapid absorption and onset of action. Intravenous injections are commonly used to provide quick relief from symptoms, deliver medications that are not easily absorbed by other routes, or administer fluids and electrolytes in cases of dehydration or severe illness. It is important that intravenous injections are performed using aseptic technique to minimize the risk of infection.

Platelet aggregation inhibitors are a class of medications that prevent platelets (small blood cells involved in clotting) from sticking together and forming a clot. These drugs work by interfering with the ability of platelets to adhere to each other and to the damaged vessel wall, thereby reducing the risk of thrombosis (blood clot formation).

Platelet aggregation inhibitors are often prescribed for people who have an increased risk of developing blood clots due to various medical conditions such as atrial fibrillation, coronary artery disease, peripheral artery disease, stroke, or a history of heart attack. They may also be used in patients undergoing certain medical procedures, such as angioplasty and stenting, to prevent blood clot formation in the stents.

Examples of platelet aggregation inhibitors include:

1. Aspirin: A nonsteroidal anti-inflammatory drug (NSAID) that irreversibly inhibits the enzyme cyclooxygenase, which is involved in platelet activation and aggregation.
2. Clopidogrel (Plavix): A P2Y12 receptor antagonist that selectively blocks ADP-induced platelet activation and aggregation.
3. Prasugrel (Effient): A third-generation thienopyridine P2Y12 receptor antagonist, similar to clopidogrel but with faster onset and greater potency.
4. Ticagrelor (Brilinta): A direct-acting P2Y12 receptor antagonist that does not require metabolic activation and has a reversible binding profile.
5. Dipyridamole (Persantine): An antiplatelet agent that inhibits platelet aggregation by increasing cyclic adenosine monophosphate (cAMP) levels in platelets, which leads to decreased platelet reactivity.
6. Iloprost (Ventavis): A prostacyclin analogue that inhibits platelet aggregation and causes vasodilation, often used in the treatment of pulmonary arterial hypertension.
7. Cilostazol (Pletal): A phosphodiesterase III inhibitor that increases cAMP levels in platelets, leading to decreased platelet activation and aggregation, as well as vasodilation.
8. Ticlopidine (Ticlid): An older P2Y12 receptor antagonist with a slower onset of action and more frequent side effects compared to clopidogrel or prasugrel.

A dose-response relationship in the context of drugs refers to the changes in the effects or symptoms that occur as the dose of a drug is increased or decreased. Generally, as the dose of a drug is increased, the severity or intensity of its effects also increases. Conversely, as the dose is decreased, the effects of the drug become less severe or may disappear altogether.

The dose-response relationship is an important concept in pharmacology and toxicology because it helps to establish the safe and effective dosage range for a drug. By understanding how changes in the dose of a drug affect its therapeutic and adverse effects, healthcare providers can optimize treatment plans for their patients while minimizing the risk of harm.

The dose-response relationship is typically depicted as a curve that shows the relationship between the dose of a drug and its effect. The shape of the curve may vary depending on the drug and the specific effect being measured. Some drugs may have a steep dose-response curve, meaning that small changes in the dose can result in large differences in the effect. Other drugs may have a more gradual dose-response curve, where larger changes in the dose are needed to produce significant effects.

In addition to helping establish safe and effective dosages, the dose-response relationship is also used to evaluate the potential therapeutic benefits and risks of new drugs during clinical trials. By systematically testing different doses of a drug in controlled studies, researchers can identify the optimal dosage range for the drug and assess its safety and efficacy.

Isoxazoles are not a medical term, but a chemical compound. They are organic compounds containing a five-membered ring consisting of one nitrogen atom, one oxygen atom, and three carbon atoms. Isoxazoles have various applications in the pharmaceutical industry as they can be used to synthesize different drugs. Some isoxazole derivatives have been studied for their potential medicinal properties, such as anti-inflammatory, analgesic, and antipyretic effects. However, isoxazoles themselves are not a medical diagnosis or treatment.

Epoprostenol receptors, also known as prostaglandin I2 (PGI2) receptors, are a type of G protein-coupled receptor that bind to and are activated by the endogenous prostaglandin Epoprostenol. These receptors play a crucial role in regulating various physiological functions, including vasodilation, inhibition of platelet aggregation, and bronchodilation.

Epoprostenol is a potent vasodilator that acts by relaxing the smooth muscle cells in the walls of blood vessels, leading to an increase in blood flow and a decrease in blood pressure. It also inhibits platelet aggregation, which helps prevent the formation of blood clots. Additionally, epoprostenol can cause bronchodilation, or relaxation of the muscles in the airways, making it useful in the treatment of pulmonary hypertension.

Epoprostenol receptors are found in various tissues throughout the body, including the vascular endothelium, platelets, and lung tissue. Activation of these receptors leads to a cascade of intracellular signaling events that ultimately result in the physiological effects of epoprostenol.

In summary, Epoprostenol receptors are G protein-coupled receptors that bind to and are activated by epoprostenol, leading to vasodilation, inhibition of platelet aggregation, and bronchodilation. These receptors play a critical role in regulating various physiological functions throughout the body.

Intra-arterial infusion is a medical procedure in which a liquid medication or fluid is delivered directly into an artery. This technique is used to deliver drugs directly to a specific organ or region of the body, bypassing the usual systemic circulation and allowing for higher concentrations of the drug to reach the target area. It is often used in cancer treatment to deliver chemotherapeutic agents directly to tumors, as well as in other conditions such as severe infections or inflammation.

Intra-arterial infusions are typically administered through a catheter that is inserted into an artery, usually under the guidance of imaging techniques such as fluoroscopy, CT, or MRI. The procedure requires careful monitoring and precise control to ensure proper placement of the catheter and accurate delivery of the medication.

It's important to note that intra-arterial infusions are different from intra venous (IV) infusions, where medications are delivered into a vein instead of an artery. The choice between intra-arterial and intra-venous infusion depends on various factors such as the type of medication being used, the location of the target area, and the patient's overall medical condition.

A "Drug Administration Schedule" refers to the plan for when and how a medication should be given to a patient. It includes details such as the dose, frequency (how often it should be taken), route (how it should be administered, such as orally, intravenously, etc.), and duration (how long it should be taken) of the medication. This schedule is often created and prescribed by healthcare professionals, such as doctors or pharmacists, to ensure that the medication is taken safely and effectively. It may also include instructions for missed doses or changes in the dosage.

Right Ventricular Function refers to the ability of the right ventricle (RV) of the heart to receive and eject blood during the cardiac cycle. The right ventricle is one of the four chambers of the heart and is responsible for pumping deoxygenated blood from the body to the lungs for re-oxygenation.

Right ventricular function can be assessed by measuring various parameters such as:

1. Right Ventricular Ejection Fraction (RVEF): It is the percentage of blood that is ejected from the right ventricle during each heartbeat. A normal RVEF ranges from 45-75%.
2. Right Ventricular Systolic Function: It refers to the ability of the right ventricle to contract and eject blood during systole (contraction phase). This can be assessed by measuring the tricuspid annular plane systolic excursion (TAPSE) or tissue Doppler imaging.
3. Right Ventricular Diastolic Function: It refers to the ability of the right ventricle to relax and fill with blood during diastole (relaxation phase). This can be assessed by measuring the right ventricular inflow pattern, tricuspid valve E/A ratio, or deceleration time.
4. Right Ventricular Afterload: It refers to the pressure that the right ventricle must overcome to eject blood into the pulmonary artery. Increased afterload can impair right ventricular function.

Abnormalities in right ventricular function can lead to various cardiovascular conditions such as pulmonary hypertension, heart failure, and arrhythmias.

"Drug evaluation" is a medical term that refers to the systematic process of assessing the pharmacological, therapeutic, and safety profile of a drug or medication. This process typically involves several stages, including preclinical testing in the laboratory, clinical trials in human subjects, and post-marketing surveillance.

The goal of drug evaluation is to determine the efficacy, safety, and optimal dosage range of a drug, as well as any potential interactions with other medications or medical conditions. The evaluation process also includes an assessment of the drug's pharmacokinetics, or how it is absorbed, distributed, metabolized, and eliminated by the body.

The findings from drug evaluations are used to inform regulatory decisions about whether a drug should be approved for use in clinical practice, as well as to provide guidance to healthcare providers about how to use the drug safely and effectively.

Adenosine diphosphate (ADP) is a chemical compound that plays a crucial role in energy transfer within cells. It is a nucleotide, which consists of a adenosine molecule (a sugar molecule called ribose attached to a nitrogenous base called adenine) and two phosphate groups.

In the cell, ADP functions as an intermediate in the conversion of energy from one form to another. When a high-energy phosphate bond in ADP is broken, energy is released and ADP is converted to adenosine triphosphate (ATP), which serves as the main energy currency of the cell. Conversely, when ATP donates a phosphate group to another molecule, it is converted back to ADP, releasing energy for the cell to use.

ADP also plays a role in blood clotting and other physiological processes. In the coagulation cascade, ADP released from damaged red blood cells can help activate platelets and initiate the formation of a blood clot.

Anticoagulants are a class of medications that work to prevent the formation of blood clots in the body. They do this by inhibiting the coagulation cascade, which is a series of chemical reactions that lead to the formation of a clot. Anticoagulants can be given orally, intravenously, or subcutaneously, depending on the specific drug and the individual patient's needs.

There are several different types of anticoagulants, including:

1. Heparin: This is a naturally occurring anticoagulant that is often used in hospitalized patients who require immediate anticoagulation. It works by activating an enzyme called antithrombin III, which inhibits the formation of clots.
2. Low molecular weight heparin (LMWH): LMWH is a form of heparin that has been broken down into smaller molecules. It has a longer half-life than standard heparin and can be given once or twice daily by subcutaneous injection.
3. Direct oral anticoagulants (DOACs): These are newer oral anticoagulants that work by directly inhibiting specific clotting factors in the coagulation cascade. Examples include apixaban, rivaroxaban, and dabigatran.
4. Vitamin K antagonists: These are older oral anticoagulants that work by inhibiting the action of vitamin K, which is necessary for the formation of clotting factors. Warfarin is an example of a vitamin K antagonist.

Anticoagulants are used to prevent and treat a variety of conditions, including deep vein thrombosis (DVT), pulmonary embolism (PE), atrial fibrillation, and prosthetic heart valve thrombosis. It is important to note that anticoagulants can increase the risk of bleeding, so they must be used with caution and regular monitoring of blood clotting times may be required.

A pulmonary embolism (PE) is a medical condition that occurs when a blood clot, often formed in the deep veins of the legs (deep vein thrombosis), breaks off and travels to the lungs, blocking one or more pulmonary arteries. This blockage can lead to various symptoms such as shortness of breath, chest pain, rapid heart rate, and coughing up blood. In severe cases, it can cause life-threatening complications like low oxygen levels, hypotension, and even death if not promptly diagnosed and treated with anticoagulant medications or thrombolytic therapy to dissolve the clot.

Oral administration is a route of giving medications or other substances by mouth. This can be in the form of tablets, capsules, liquids, pastes, or other forms that can be swallowed. Once ingested, the substance is absorbed through the gastrointestinal tract and enters the bloodstream to reach its intended target site in the body. Oral administration is a common and convenient route of medication delivery, but it may not be appropriate for all substances or in certain situations, such as when rapid onset of action is required or when the patient has difficulty swallowing.

Angiography is a medical procedure in which an x-ray image is taken to visualize the internal structure of blood vessels, arteries, or veins. This is done by injecting a radiopaque contrast agent (dye) into the blood vessel using a thin, flexible catheter. The dye makes the blood vessels visible on an x-ray image, allowing doctors to diagnose and treat various medical conditions such as blockages, narrowing, or malformations of the blood vessels.

There are several types of angiography, including:

* Cardiac angiography (also called coronary angiography) - used to examine the blood vessels of the heart
* Cerebral angiography - used to examine the blood vessels of the brain
* Peripheral angiography - used to examine the blood vessels in the limbs or other parts of the body.

Angiography is typically performed by a radiologist, cardiologist, or vascular surgeon in a hospital setting. It can help diagnose conditions such as coronary artery disease, aneurysms, and peripheral arterial disease, among others.

Retrospective studies, also known as retrospective research or looking back studies, are a type of observational study that examines data from the past to draw conclusions about possible causal relationships between risk factors and outcomes. In these studies, researchers analyze existing records, medical charts, or previously collected data to test a hypothesis or answer a specific research question.

Retrospective studies can be useful for generating hypotheses and identifying trends, but they have limitations compared to prospective studies, which follow participants forward in time from exposure to outcome. Retrospective studies are subject to biases such as recall bias, selection bias, and information bias, which can affect the validity of the results. Therefore, retrospective studies should be interpreted with caution and used primarily to generate hypotheses for further testing in prospective studies.

I'm sorry for any confusion, but "Japan" is not a medical term. Japan is the name of a country, officially known as Nippon-koku or Nihon-koku in Japanese, and is located in East Asia. It is an island nation in the Pacific Ocean with a population of about 126 million people.

If you have any medical questions or terms that you would like me to define, please let me know!

Medical survival rate is a statistical measure used to determine the percentage of patients who are still alive for a specific period of time after their diagnosis or treatment for a certain condition or disease. It is often expressed as a five-year survival rate, which refers to the proportion of people who are alive five years after their diagnosis. Survival rates can be affected by many factors, including the stage of the disease at diagnosis, the patient's age and overall health, the effectiveness of treatment, and other health conditions that the patient may have. It is important to note that survival rates are statistical estimates and do not necessarily predict an individual patient's prognosis.

Epoprostenol does not appear to be of use. The prevalence of this disease is estimated to be < 1/million. The usual age at ... Respir Med 131:215-219 Akagi S, Nakamura K, Matsubara H, Ogawa A, Sarashina T, Ejiri K, Ito H (2015) Epoprostenol therapy for ...
"Epoprostenol". Drug Information Portal. U.S. National Library of Medicine. "Epoprostenol sodium". Drug Information Portal. U.S ... Specifically, epoprostenol is given to patients with class III or class IV PAH.[citation needed] Prostacyclin, which has a half ... March 2003). "Inhaled epoprostenol (prostacyclin) and pulmonary hypertension before cardiac surgery". The Journal of Thoracic ... When used as a drug, it is also known as epoprostenol. The terms are sometimes used interchangeably. Prostacyclin (PGI2) ...
Major drugs in this category include PGI2 itself (i.e. epoprostenol), iloprost, treprostinil, and beraprost with epoprostenol ... Epoprostenol causes improvements in hemodynamic parameters and oxygenation in patients suffering the acute respiratory distress ... McGinn K, Reichert M (January 2016). "A Comparison of Inhaled Nitric Oxide Versus Inhaled Epoprostenol for Acute Pulmonary ... Sitbon O, Vonk Noordegraaf A (January 2017). "Epoprostenol and pulmonary arterial hypertension: 20 years of clinical experience ...
Sarcoidosis associated pulmonary hypertension: Outcome with long-term epoprostenol treatment (submitted). Klings ES, Odhiambo, ...
Epoprostenol therapy can lower PAP by 29-46% and PVR by 21-71%., Ilioprost shows no evidence of generating tolerance, increases ... Epoprostenol and ilioprost (a more stable, longer acting variation) can and does successfully bridge for patients to transplant ... Successful use of chronic epoprostenol as a bridge to liver transplant in severe PPHTN. Transplant 1998 4:457 Kuo PC, Johnson ... Prostacyclin - PGI2, an arachidonic acid derived lipid mediator (Epoprostenol, Flolan, Treprostenil) - is a vasodilator and, at ...
Veletri (epoprostenol for injection): is approved by the U.S. Food and Drug Administration (FDA) for the long-term intravenous ... "FDA approves brand name VELETRI for Actelion's epoprostenol for injection therapy". News Medical Lifesciences (Press release). ...
epoprostenol as an alternate to oral therapy non-responders for the treatment of pulmonary arterial hypertension". Curr Med Res ... But like native prostacyclin, the structure of the epoprostenol molecule proved to be unstable in solution, prone to rapid ... In people with pulmonary arterial hypertension requiring transition from epoprostenol sodium (Flolan), treprostinil is ... The collaboration produced a synthetic molecule which was given the name epoprostenol. ...
Pulmonary hypertension may be treated with epoprostenol, treprostinil, bosentan, and possibly aerolized iloprost. Nintedanib ...
Epoprostenol (synthetic prostacyclin) is given via continuous infusion that requires a semi-permanent central venous catheter. ... Medications specifically used to treat pulmonary hypertension include epoprostenol, treprostinil, iloprost, bosentan, ... epoprostenol, or nitric oxide are considered vasoreactive. Of these, only half of the patients are responsive to calcium ...
... category for Epoprostenol. t.co/XCYZlqLOCE" (Tweet). Archived from the original on 13 February 2022. Retrieved 18 February 2022 ...
Cruz JE, Ward A, Anthony S, Chang S, Bae HB, Hermes-DeSantis ER (2016). "Evidence for the Use of Epoprostenol to Treat ...
Under an agreement with GlaxoSmithKline, Myogen marketed Flolan (epoprostenol sodium) in the United States for the treatment of ...
Dextroamphetamine Diazepam Dihydrocodeine Doxorubicin HCl Emtricitabine/tenofovir Epirubicin HCl Eplerenon Epoprostenol Sodium ...
Epoprostenol Egan, Donald F.; Wilkins, Robert L.; Stoller, James K.; Kacmarek, Robert M. (2009). Egan's fundamentals of ...
... epoprostenol MeSH D10.251.355.255.100.825 - thromboxanes MeSH D10.251.355.255.100.825.800 - thromboxane a2 MeSH D10.251.355.255 ... epoprostenol MeSH D10.251.355.255.550.700 - prostaglandins, synthetic MeSH D10.251.355.255.550.700.125 - iloprost MeSH D10.251. ...
... epoprostenol) Flonase (fluticasone propionate) Flovent (fluticasone propionate) Fortum (ceftazidime) Halfan (halofantrine) ...
B01AC05 Ticlopidine B01AC06 Acetylsalicylic acid B01AC07 Dipyridamole B01AC08 Carbasalate calcium B01AC09 Epoprostenol B01AC10 ...
... epoprostenol MeSH D23.469.050.175.800 - thromboxanes MeSH D23.469.050.175.800.800 - thromboxane a2 MeSH D23.469.050.175.800.810 ...
... epoprostenol MeSH D12.776.543.750.100.200.700.600 - receptors, prostaglandin e MeSH D12.776.543.750.100.200.700.800 - receptors ... epoprostenol MeSH D12.776.543.750.075.700.600 - receptors, prostaglandin e MeSH D12.776.543.750.075.700.800 - receptors, ...
... epoprostenol) manage to considerably improve morbidity and mortality. Further investigation into appropriate treatment options ...
... opposes actions of TXA2 Epoprostenol is a prostacyclin that is used to inhibit platelet aggregation during renal dialysis (with ...
... epoprostenol (INN) epostane (INN) eprazinone (INN) epratuzumab (INN) eprinomectin (INN) epristeride (INN) eprobemide (INN) ...
Study objective: To determine the efficacy of continuous intravenous infusion of prostacyclin (epoprostenol) in primary ... Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized ...
Infusions of epoprostenol (prostacyclin, PGI2) at a dose of 5 ng/kg/min resulted in a reduction of CBF of about 10% after ... Effect of indomethacin on cerebral blood flow, carbon dioxide reactivity and the response to epoprostenol (prostacyclin) ... Effect of indomethacin on cerebral blood flow, carbon dioxide reactivity and the response to epoprostenol (prostacyclin) ...
Epoprostenol is indicated for the treatment of pulmonary arterial hypertension (PAH) (idiopathic or heritable PAH and PAH ... Epoprostenol is indicated for:. Pulmonary Arterial Hypertension. Epoprostenol is indicated for the treatment of pulmonary ... Epoprostenol is indicated for the use in haemodialysis in emergency situations when use of heparin carries a high risk of ... Epoprostenol 0.5 mg and 1.5 mg (Powder and Solvent for Solution for Infusion) ...
The epoprostenol infusion regimen involved continuous intravenous epoprostenol that was initiated at 2 ng/kg/min and increased ... Intravenous Epoprostenol Warranted for Scleroderma Spectrum Digital Vasculopathy. The use of intravenous epoprostenol infusion ... The target epoprostenol infusion rate of 8 ng/kg/min was achieved in 20 of the patients. The infusion rate was titrated above ... Forty-six epoprostenol infusions were administered to the 35 patients.. Twenty-nine of the 46 infusions produced improvement ...
Iloprost is a drug that can help prevent your condition causing damage to your body. It can sometimes cause side effects, but many of these are rare or uncommon.
Retrieved from "https://www.wikem.org/w/index.php?title=Epoprostenol_(prostacyclin)&oldid=122244" ...
The effect of epoprostenol on heart rate in animals varies with dose. At low doses, there is vagally mediated brudycardia, but ... Epoprostenol (PGI2) is a member of the family of prostaglandins that is derived from arachidonic acid. The major ... Epoprostenol is metabolized to 2 primary metabolites: 6-keto-PGF1α (formed by spontaneous degradation) and 6, 15-diketo-13, 14- ... Epoprostenol has two major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds, ...
Veletri (Epoprostenol) for Pulmonary Hypertension. 66 people have indicated they have taken Veletri ...
Download CSV: all data on Epoprostenol sodium or data on Epoprostenol sodium by Sub-ICB Location. ... Epoprostenol sodium (0208010E0). Part of chapter 2 Cardiovascular System, section 2.8 Anticoagulants and protamine, paragraph ... High-level prescribing trends for Epoprostenol sodium (BNF code 0208010E0) across all GP practices in NHS England for the last ...
Epoprostenol is a strong vasodilator of all vascular beds. It may decrease thrombogenesis and platelet clumping in the lungs by ... Usefulness of epoprostenol therapy in the severely ill adolescent/adult with Eisenmenger physiology. Am J Cardiol. 2003 Mar 1. ... Initiate administration of epoprostenol under close observation in the intensive care unit (ICU), with a right heart flotation ... Ivy DD, Doran A, Claussen L, Bingaman D, Yetman A. Weaning and discontinuation of epoprostenol in children with idiopathic ...
OBJECTIVES: This study sought to determine the long-term effects of continuous infusion of epoprostenol (epo) therapy on ... Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion.. S M ...
Explore the 6 papers that mention a possible interaction between Capsaicin and Epoprostenol. ...
Epoprostenol in pulmonary arterial hypertension. / Jacobs, W.; Vonk Noordegraaf, A. In: Expert Opinion on Drug Metabolism and ... Epoprostenol in pulmonary arterial hypertension. Expert Opinion on Drug Metabolism and Toxicology. 2009;5(1):83-90. doi: https ... Jacobs, W. ; Vonk Noordegraaf, A. / Epoprostenol in pulmonary arterial hypertension. In: Expert Opinion on Drug Metabolism and ... Jacobs, W., & Vonk Noordegraaf, A. (2009). Epoprostenol in pulmonary arterial hypertension. Expert Opinion on Drug Metabolism ...
80% Starting Epoprostenol Dose. 30% Starting Epoprostenol Dose. 3. 60% Starting Epoprostenol Dose. 50% Starting Epoprostenol ... 40% Starting Epoprostenol Dose. 70% Starting Epoprostenol Dose. 5. 20% Starting Epoprostenol Dose. 90% Starting Epoprostenol ... 5% Starting Epoprostenol Dose. 110% Starting Epoprostenol Dose. 7. 0. 110% Starting Epoprostenol Dose + additional 5-10% ... Initiate Remodulin at a recommended dose of 10% of the current epoprostenol dose, and then escalate as the epoprostenol dose is ...
... along with epoprostenol, alemtuzumab, and fumaric acid. [24] ...
Epoprostenol / pharmacology * Female * Humans * Intestinal Mucosa / chemistry * Intestinal Mucosa / cytology * Leukotriene B4 ...
Detailed drug Information for Acnex Topical. Includes common brand names, drug descriptions, warnings, side effects and dosing information.
The antihistamine in this medicine will add to the effects of alcohol and other central nervous system (CNS) depressants (medicines that slow down the nervous system, possibly causing drowsiness). Some examples of CNS depressants are other antihistamines or medicine for hay fever, other allergies, or colds; sedatives, tranquilizers, or sleeping medicine; prescription pain medicine or narcotics; barbiturates; medicine for seizures; muscle relaxants; or anesthetics, including some dental anesthetics. Check with your doctor before taking any of the above while you are taking this medicine.. Also, stomach problems may be more likely to occur if you drink alcoholic beverages while taking a medicine that contains aspirin. In addition, drinking large amounts of alcoholic beverages while taking a medicine that contains acetaminophen may cause liver damage.. The antihistamine in this medicine may cause some people to become drowsy, dizzy, or less alert than they are normally. Make sure you know how you ...
Epoprostenol. For more information on this medication choose from the list of selections below. ...
Global Epoprostenol Market Research Report 2022 - Future Opportunities, Latest Trends, In-depth Analysis, and Forecast To 2029 ... Report Title : Global Epoprostenol Market Research Report 2022 - Future Opportunities, Latest Trends, In-depth Analysis, and ...
Epoprostenol does not appear to be of use. The prevalence of this disease is estimated to be < 1/million. The usual age at ... Respir Med 131:215-219 Akagi S, Nakamura K, Matsubara H, Ogawa A, Sarashina T, Ejiri K, Ito H (2015) Epoprostenol therapy for ...
Tags: acute respiratory distress syndromeepoprostenolhypoxaemiaICUinhaledintensive carenitric oxidepulmonary hypertensionQ&A ... There is a new UKMi Q&A - Is there a role for inhaled epoprostenol, inhaled nitric oxide or sildenafil to treat secondary ... New Q&A - Is there a role for inhaled epoprostenol, inhaled nitric oxide or sildenafil to treat secondary pulmonary ...
23.1, p = 0.002). Epoprostenol responders had a median OI decrease of 11.6 within 4 h (p = 0.017) with a significant response ... 23.1, p = 0.002). Epoprostenol responders had a median OI decrease of 11.6 within 4 h (p = 0.017) with a significant response ... 23.1, p = 0.002). Epoprostenol responders had a median OI decrease of 11.6 within 4 h (p = 0.017) with a significant response ... 23.1, p = 0.002). Epoprostenol responders had a median OI decrease of 11.6 within 4 h (p = 0.017) with a significant response ...
Epoprostenol. *Eprex®(Epoetin Alpha)see Epoetin Alfa, Injection. *Eprontia ®see Topiramate. *Eprosartan ...
Caripul (epoprostenol) * carvedilol (Apo-Carvedilol, Auro-Carvedilol, Ava-Carvedilol, Carvedilol by Meliapharm, Carvedilol by ...
Flolan 0.5 mg & 1.5 mg Powder and Solvent for Solution for Infusion (with pH 12 solvent) - Patient Information Leaflet (PIL) by GlaxoSmithKline UK
Epoprostenol. Etanercept. Factor IX Felbamato. Fenofibrato. Fexofenadina. Floxuridina. Fludarabina. Fluocinolona. ...
epoprostenol sodium) Pulmonary Arterial Hypertension For more information, please download:. Data Sheet. Consumer Medicine ...
Inhaled epoprostenol for acute respiratory distress syndrome Nicole M. Schroeder PharmD, BCPS, BCCCP,Danielle R. Castiello BSN ...
  • High-level prescribing trends for Epoprostenol sodium (BNF code 0208010E0) across all GP practices in NHS England for the last five years. (openprescribing.net)
  • all data on Epoprostenol sodium or data on Epoprostenol sodium by Sub-ICB Location . (openprescribing.net)
  • Sterile Diluent for Flolan or Sterile Diluent for Epoprostenol), Sterile Water for Injection, or 0.9% Sodium Chloride Injection prior to administration. (rxlist.com)
  • Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). (nih.gov)
  • To determine the efficacy of continuous intravenous infusion of prostacyclin (epoprostenol) in primary pulmonary hypertension. (nih.gov)
  • Effect of indomethacin on cerebral blood flow, carbon dioxide reactivity and the response to epoprostenol (prostacyclin) infusion in man. (bmj.com)
  • Infusions of epoprostenol (prostacyclin, PGI2) at a dose of 5 ng/kg/min resulted in a reduction of CBF of about 10% after placebo but no significant change in CBF after indomethacin. (bmj.com)
  • In some patients, chronic prostacyclin analogue therapy (epoprostenol) can be of benefit, particularly as a bridge to heart-lung transplantation. (medscape.com)
  • Treat side effects normally associated with prostacyclin and prostacyclin analogs first by decreasing the dose of epoprostenol. (medscape.com)
  • Epoprostenol is indicated for the treatment of pulmonary arterial hypertension (PAH) (idiopathic or heritable PAH and PAH ociated with connective tissue diseases) in patients with WHO Functional Cl III-IV symptoms to improve exercise capacity. (farmavita.net)
  • The possibility of pulmonary hypertension was assessed using echocardiography in each patient before epoprostenol was ended. (sidemast.org)
  • Epoprostenol has two major pharmacological actions: (1) direct vasodilation of pulmonary and systemic arterial vascular beds, and (2) inhibition of platelet aggregation. (lgmpharma.com)
  • Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. (qxmd.com)
  • This study sought to determine the long-term effects of continuous infusion of epoprostenol (epo) therapy on survival and pulmonary artery pressure in patients with primary pulmonary hypertension (PPH). (qxmd.com)
  • Jacobs, W & Vonk Noordegraaf, A 2009, ' Epoprostenol in pulmonary arterial hypertension ', Expert Opinion on Drug Metabolism and Toxicology , vol. 5, no. 1, pp. 83-90. (amsterdamumc.org)
  • Respir Med 131:215-219 Akagi S, Nakamura K, Matsubara H, Ogawa A, Sarashina T, Ejiri K, Ito H (2015) Epoprostenol therapy for pulmonary arterial hypertension. (wikipedia.org)
  • Is there a role for inhaled epoprostenol, inhaled nitric oxide or sildenafil to treat secondary pulmonary hypertension and hypoxaemia in ICU patients with acute respiratory distress syndrome? (wales.nhs.uk)
  • Objectives: Evaluate the short-term effects of IV epoprostenol in neonates with persistent pulmonary hypertension (PPHN) of the newborn. (elsevierpure.com)
  • The use of intravenous epoprostenol infusion is generally safe and effective in the treatment of scleroderma spectrum digital vasculopathy. (sidemast.org)
  • The use of intravenous epoprostenol infusion is generally safe and effective in the treatment of scleroderma spectrum digital vasculopathy, according to results of a retrospective study presented here on November 13 at the 2016 Annual Scientific Meeting of the American College of Rheumatology/Association of Rheumatology Health Professionals. (sidemast.org)
  • The epoprostenol infusion regimen involved continuous intravenous epoprostenol that was initiated at 2 ng/kg/min and increased every 15 minutes to a maximum dose of 8 ng/kg/min. (sidemast.org)
  • The target epoprostenol infusion rate of 8 ng/kg/min was achieved in 20 of the patients. (sidemast.org)
  • In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. (rxlist.com)
  • Veletri may be referred to by its drug name, epoprostenol. (myphteam.com)
  • Forty-six epoprostenol infusions were administered to the 35 patients. (sidemast.org)
  • Study Design: We reviewed 36 patients with inhaled nitric oxide (iNO) refractory PPHN placed on IV epoprostenol from 2010 to 2015. (elsevierpure.com)
  • The major pharmacological actions of epoprostenol is ultimately inhibition of platelet aggregation. (lgmpharma.com)
  • Epoprostenol (PGI2) is a member of the family of prostaglandins that is derived from arachidonic acid. (lgmpharma.com)
  • Fourteen additional minor metabolites have been isolated from urine, indicating that epoprostenol is extensively metabolized in humans. (lgmpharma.com)
  • The authors conclude that epoprostenol is a possible therapeutic option to improve the consistency of patient care in the treatment of scleroderma spectrum digital vasculopathy. (sidemast.org)
  • Treprostinil injection is also used to treat PAH when another medication (epoprostenol) did not help or could not be tolerated. (safemedication.com)
  • The effect of epoprostenol on heart rate in animals varies with dose. (lgmpharma.com)
  • [2] Sildenafil-induced delay in clinical worsening is demonstrated when sildenafil was used concomitantly with epoprostenol therapy. (nih.gov)
  • If hypertension was evident, appropriate treatment was initiated before discontinuation of epoprostenol, typically a phosphodiesterase type 5 inhibitor. (sidemast.org)
  • Most events were self-limiting and resolved with reduction or withholding of epoprostenol. (lgmpharma.com)
  • Conclusion: In infants with iNO-refractory PPHN, initiation of IV epoprostenol was associated with a significant and rapid OI reduction among responders. (elsevierpure.com)
  • Presentation title: Use of Intravenous Epoprostenol As a Treatment for the Digital Vasculopathy Associated with the Scleroderma Spectrum of Diseases. (sidemast.org)
  • Additional pharmacologic effects of epoprostenol in animals include bronchodilation, inhibition of gastric acid secretion, and decreased gastric emptying. (lgmpharma.com)
  • Epoprostenol is metabolized to 2 primary metabolites: 6-keto-PGF1α (formed by spontaneous degradation) and 6, 15-diketo-13, 14-dihydro-PGF1α (enzymatically formed), both of which have pharmacological activity orders of magnitude less than epoprostenol in animal test systems. (lgmpharma.com)
  • At low doses, there is vagally mediated brudycardia, but at higher doses, epoprostenol causes reflex tachycardia in response to direct vasodilation and hypotension. (lgmpharma.com)
  • Epoprostenol responders had a median OI decrease of 11.6 within 4 h (p = 0.017) with a significant response persisting through 24 h. (elsevierpure.com)
  • Effect of Nebulizer Position on Aerosolized Epoprostenol Delivery in an Adult Lung Model. (rush.edu)
  • [ 53 ] Nonetheless, the development of acute fulminant pulmonary edema and death have been reported with the infusion of intravenous epoprostenol, even at a very low dose. (medscape.com)
  • 2. Intravenous epoprostenol in inoperable chronic thromboembolic pulmonary hypertension. (nih.gov)
  • 1 - 4 The first synthetic prostacyclin used in the treatment of PH was intravenous epoprostenol. (dovepress.com)
  • Continuous intravenous epoprostenol improves exercise capacity, hemodynamics, and survival in pulmonary hypertension and is the preferred treatment option for the most critically ill patients. (conduent.com)
  • Epoprostenol sodium (Flolan-Glaxo Wellcome), also known as prostacyclin, has been approved by the US Food and Drug Administration for continuous intravenous treatment of primary pulmonary hypertension. (nih.gov)
  • Epoprostenol sodium is a prostanoid vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise capacity. (nih.gov)
  • Intravenous and inhaled epoprostenol for primary pulmonary hypertension during pregnancy and delivery. (nih.gov)
  • As previously stated, the prostaglandin epoprostenol, a vasodilator, has been reported to have some hemodynamic benefits in patients with pulmonary veno-occlusive disease (PVOD) and has been shown to reverse the increase in pulmonary venule vasomotor tone that occurs in this condition. (medscape.com)
  • Respir Med 131:215-219 Akagi S, Nakamura K, Matsubara H, Ogawa A, Sarashina T, Ejiri K, Ito H (2015) Epoprostenol therapy for pulmonary arterial hypertension. (wikipedia.org)
  • aspirin/citric acid/sodium bicarbonate and epoprostenol both increase anticoagulation. (medscape.com)
  • The individual has a diagnosis of PAH (WHO Group 1) and requires transition from epoprostenol sodium (e.g. (bcbsnd.com)
  • Oral medications, including nifedipine (a blood pressure medication), epoprostenol (a prostaglandin), or a drug that affects the nerves (selective serotonin reuptake inhibitor), such as fluoxetine. (skinsight.com)
  • also used to treat PAH when another medication ( epoprostenol ) did not help or could not be tolerated. (nih.gov)
  • Pricing is displayed for EPOPROSTENOL , a generic medication. (americaspharmacy.com)
  • In addition to its action as a vasodilator, epoprostenol also contributes to the inhibition of platelet aggregation and plays a role in the inhibition of smooth muscle proliferation. (medscape.com)
  • aceclofenac and epoprostenol both increase anticoagulation. (medscape.com)
  • alfalfa and epoprostenol both increase anticoagulation. (medscape.com)
  • aspirin and epoprostenol both increase anticoagulation. (medscape.com)
  • bemiparin and epoprostenol both increase anticoagulation. (medscape.com)
  • celecoxib and epoprostenol both increase anticoagulation. (medscape.com)
  • choline magnesium trisalicylate and epoprostenol both increase anticoagulation. (medscape.com)
  • Use epoprostenol injection exactly as directed. (medlineplus.gov)
  • Epoprostenol injection is usually used under medical supervision when your treatment is started and when your dose is changed. (medlineplus.gov)
  • Ask your healthcare provider if you have any questions about how to infuse epoprostenol injection. (medlineplus.gov)
  • It is important for you to tell your doctor how you are feeling during your treatment with epoprostenol injection. (medlineplus.gov)
  • Epoprostenol injection may cause low blood pressure. (medlineplus.gov)
  • Do not stop using epoprostenol injection without talking to your doctor. (medlineplus.gov)
  • Epoprostenol injection is not available in pharmacies. (medlineplus.gov)
  • tell your doctor and pharmacist if you are allergic to epoprostenol, any other medications, or any of the ingredients in epoprostenol injection. (medlineplus.gov)
  • Your doctor may tell you not to use epoprostenol injection. (medlineplus.gov)
  • These highlights do not include all the information needed to use EPOPROSTENOL FOR INJECTION safely and effectively. (nih.gov)
  • See full prescribing information for EPOPROSTENOL FOR INJECTION. (nih.gov)
  • Epoprostenol for injection solution reconstituted and immediately diluted to the final concentration in the drug delivery reservoir can be administered per the conditions of use as outlined in Table 1. (nih.gov)
  • Injection: 10 mL single-dose vial with 0.5 mg (500,000 ng) or 1.5 mg (1,500,000 ng) epoprostenol. (nih.gov)
  • Continuous intravenous administration of epoprostenol remains the treatment of choice in WHO functional class IV patients. (nih.gov)
  • Initial observational data from patients treated with infused epoprostenol indicated that patients with less severe functional impairment and no history of right heart failure at the start of treatment had better outcomes [ 5 , 6 ]. (ersjournals.com)
  • Inhaled epoprostenol and intravenous milrinone were administered to treat acute right ventricular failure and to reduce right ventricular afterload. (alliedacademies.org)
  • The physiologically active and stable hydrolysis product of EPOPROSTENOL . (bvsalud.org)
  • Epoprostenol may improve the ability to exercise and slow the worsening of symptoms in patients with PAH. (medlineplus.gov)
  • Hi everyone, Does your institution have restrictions on pregnant providers/caregivers entering the room of patients receiving inhaled epoprostenol (via mechanical ventilator circuit or high flow nasal cannula)? (sccm.org)
  • Great point-I was told not to go in the room of patients on inhaled epoprostenol when I was pregnant, but there was no signage on the door someone just told me not to go in the room. (sccm.org)
  • S0155 is a valid 2023 HCPCS code for Sterile dilutant for epoprostenol, 50 ml or just " Epoprostenol dilutant " for short, used in Other medical items or services . (hcpcs.codes)